Cellectis S.A. (CMVLF)
Cellectis S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Paris, FR. The stock last traded at $3.47, up 12.66% on the session, giving a market capitalisation of $251.9M. On trailing twelve-month figures it carries a trailing P/E of -4.55, a net margin of -98.7%. Its beta of 2.75 implies it has historically moved more than the broad market.
Cellectis S.A. is a clinical-stage biotechnology firm dedicated to advancing immuno-oncology therapies. Their core technology involves engineering T-cells with gene editing to express chimeric antigen receptors (CARs), enabling these modified cells to precisely target and destroy cancer cells. The company's operations are structured into two principal divisions: Therapeutics and Plants. Its robust development pipeline includes several crucial product candidates. Notable among these is UCART19, an allogeneic T-cell treatment designed for CD19-expressing blood cancers like acute lymphoblastic leukemia. They are also progressing ALLO-501 and ALLO-501A, aimed at tackling relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. Further candidates encompass ALLO-316 for renal cell carcinoma, UCART123 for acute myeloid leukemia, and UCART22 for B-cell acute lymphoblastic leukemia. Additionally, the company is advancing UCARTCS1 and ALLO-715 in its efforts against multiple myeloma. Cellectis has forged significant strategic partnerships with organizations such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. Furthermore, it maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was established in 1999 and its headquarters are located in Paris, France.
Cellectis S.A. is most often compared with the following Healthcare names: